Truqap® (Capivasertib) for HR+ HER2– Breast Cancer

What Truqap® Is and How It Works

Truqap (capivasertib) is an oral AKT inhibitor used with fulvestrant for adults with hormone receptor–positive, HER2‑negative, locally advanced or metastatic breast cancer that shows PIK3CA, AKT1, or PTEN alterations. It blocks AKT signaling in the PI3K/AKT pathway to slow tumor cell survival and proliferation. Many people compare options when paying without insurance, and some choose to buy truqap (capivasertib) online at Canadian prices.

YouDrugstore is a licensed Canadian pharmacy headquartered in Manitoba, where licensed pharmacists review prescriptions before dispensing; we offer brand and generic medicines at Canadian prices and also carry OTC health products.

We partner with licensed, vetted international pharmacies so you receive authentic brand medications, a broad selection, and affordable pricing.

Truqap is supplied as oral tablets and is taken in cycles. It is given with fulvestrant injections. This targeted therapy is often used after disease progression on an aromatase inhibitor, with or without a CDK4/6 inhibitor. Your oncology team will confirm that your tumor has an eligible alteration before starting therapy.

Dosage and Usage

• Typical adult regimen: 400 mg by mouth twice daily, about 12 hours apart, for 4 consecutive days each week, followed by 3 days off (4‑on/3‑off schedule).
• Use with fulvestrant 500 mg intramuscularly per standard schedule (Day 1 and 15 of Cycle 1, then Day 1 of subsequent 28‑day cycles).
• Tablets may be taken with or without food. Swallow tablets whole; do not crush, split, or chew.
• Start on a consistent weekday to keep the 4‑day dosing pattern easy to track across cycles.
• Avoid strong CYP3A inhibitors/inducers and grapefruit/grapefruit juice. Discuss all medications and supplements with the care team.
• Missed dose: if a dose is missed or vomiting occurs after a dose, do not take an extra tablet; take the next scheduled dose.
• Dose reductions or interruptions may be required for side effects or interactions. Follow the prescriber’s plan.
• Monitoring often includes blood glucose, A1C, electrolytes, and liver tests before and during treatment.

• Store at 20–25 °C (68–77 °F); brief excursions 15–30 °C (59–86 °F) are acceptable.
• Keep tablets in the original, tightly closed container with desiccant; protect from moisture.
• Do not store in bathrooms or near heat sources. Keep out of reach of children and pets.
• For travel, carry your medication in hand luggage with the pharmacy label. Pack extra for delays.
• If crossing time zones, keep the 12‑hour spacing and 4‑on/3‑off weekly rhythm. Set phone reminders.
• Do not repack into unlabeled bags. Use a pill organizer only if it keeps tablets dry.

Benefits and Savings

In clinical studies, adding capivasertib to fulvestrant improved progression‑free survival in patients with the specified pathway alterations, supporting its role after aromatase inhibitor therapy. As an oral targeted treatment, it fits easily into daily routines. The intermittent 4‑on/3‑off schedule may help tolerability while maintaining activity.

Patients value predictable dosing with tablets and the ability to continue routine appointments for injections. The combination leverages endocrine therapy and targeted pathway blockade for complementary control. Discuss how this approach fits with prior CDK4/6 inhibitor exposure and current disease burden.

You can expect meaningful savings ordering from Canada. Many customers see 60–80% lower costs vs typical US prices on truqap (capivasertib) price, depending on strength and pack size. Multi‑month supplies and select bulk promotions can lower per‑month costs further. Reorder reminders help prevent gaps in therapy, including for those managing truqap capivasertib without insurance.

For current offers, see our truqap (capivasertib) coupon.

Side Effects and Safety

• Diarrhea or loose stools
• Skin rash, acneiform rash, dry or itchy skin
• Nausea, vomiting, abdominal discomfort
• Decreased appetite, fatigue
• Stomatitis or mouth sores
• Headache
• Elevated blood glucose or new/worsening hyperglycemia

Serious but less common risks include severe hyperglycemia (including ketoacidosis), severe rash, infections, and liver test abnormalities. Capivasertib can harm an unborn baby; use effective contraception and avoid breastfeeding during treatment. Drug interactions are significant with strong CYP3A inhibitors or inducers; avoid grapefruit. If insulin or sulfonylureas are used for diabetes, clinicians may adjust those doses to reduce hypoglycemia risk. Seek urgent care for signs of severe reactions or uncontrolled blood sugars.

Onset Time

Some side effects such as diarrhea or rash may occur in the first 1–2 weeks, most often during the initial cycles. Supportive care measures are commonly started early as needed.

Tumor responses and disease control are typically assessed after 1–2 cycles on imaging and by symptom review. Many patients who benefit observe stabilization or response within 8–12 weeks, with continued monitoring each cycle. Your oncology team will tailor scan frequency and labs to your history and prior therapies.

Compare With Alternatives

For HR‑positive, HER2‑negative advanced breast cancer with a PIK3CA mutation, alpelisib with fulvestrant is another targeted option. It inhibits PI3K‑alpha rather than AKT, with a different side‑effect profile, especially regarding hyperglycemia and rash. Genomic results and prior therapies guide the choice between AKT and PI3K pathway inhibition.

Everolimus (mTOR inhibitor) with endocrine therapy is an additional strategy after aromatase inhibitor exposure. It affects a downstream node of the PI3K/AKT/mTOR pathway and has distinct adverse effects, such as stomatitis and metabolic changes.

We also supply other oncology therapies for different cancers, including Bavencio® and Zytiga®. These are not substitutes for Truqap but show the range of targeted and immuno‑oncology treatments available through our pharmacy.

Combination Therapy

• Truqap with fulvestrant is the approved combination; follow the injection schedule alongside the 4‑on/3‑off tablet cycle.
• Use after progression on an aromatase inhibitor, with or without a prior CDK4/6 inhibitor, per guidelines and biomarker status.
• Supportive care may include antidiarrheals, topical steroids, antihistamines, and skin‑care routines for rash.
• If diabetes medicines are used, doses may be adjusted to limit hypoglycemia during combination treatment.
• Avoid strong CYP3A inhibitors/inducers; consider alternative agents or adjust capivasertib dose per prescriber.

Patient Suitability and Cost-Saving Tips

Good candidates are adults with HR‑positive, HER2‑negative, locally advanced or metastatic breast cancer and confirmed tumor alterations in PIK3CA, AKT1, or PTEN. Adequate organ function and manageable baseline blood glucose support safer use. Prior exposure to aromatase inhibitors, and often to a CDK4/6 inhibitor, is typical before starting this regimen.

Those with uncontrolled diabetes, active severe infections, significant uncontrolled rash, or who are pregnant or breastfeeding may not be suitable. Clinicians review lab trends, ECGs if indicated, comorbidities, and all medications to manage interactions and risks. Dose interruptions and reductions are common tools to handle tolerability.

To manage the truqap (capivasertib) cost, consider a longer supply when appropriate. Multi‑month fills can reduce shipping frequency and may lower the per‑month expense. Watch for truqap (capivasertib) discount opportunities or truqap (capivasertib) bulk pricing when available. You can set gentle refill reminders so you do not run out during travel or around scan appointments. Patients paying out of pocket often compare the truqap (capivasertib) cash price and truqap capivasertib out of pocket estimates before starting.

Authoritative Sources

FDA Prescribing Information for Truqap (capivasertib)

AstraZeneca Truqap Product Information

Health Canada Drug Product Database

Order Truqap® from YouDrugstore.com: add to cart, upload your prescription, and we ship with prompt, express, cold-chain handling.

This content is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment. Always speak with a qualified healthcare provider about your therapy.